H.C. Wainwright continued to express strong support for Invivyd Inc. (NASDAQ: IVVD) by sustaining a Buy rating and a $10.00 price target after a January 13 meeting with the company’s top executives. Though Invivyd's shares have already surged 428% over the previous year to $2.21, the target price represents an additional 352% upside, underscoring high expectations for the company’s near-term value proposition.
The investment firm highlighted Invivyd’s management focus on delivering pivotal Phase 3 topline data for VYD2311 anticipated in August, viewing it as a critical catalyst alongside the ongoing commercial momentum of the PEMGARDA (pemivibart) franchise. According to InvestingPro, Invivyd reported a strong gross profit margin of 93.34%, a noteworthy metric despite the expectation that profitability will not be achieved within the current fiscal year.
During their in-depth discussions with Invivyd’s leadership, H.C. Wainwright gained insight into projected timelines and regulatory milestones. Management elaborated on how a Fast Track designation could expedite the evaluation of a rolling biologics license application (BLA) following the presentation of clinical data, potentially accelerating product availability.
The analysis firm emphasized PEMGARDA’s role as a core commercial asset, instrumental in advancing Invivyd’s infrastructure, market access, and manufacturing capabilities. This strategic positioning is intended to lay the groundwork for a smooth introduction of VYD2311 into the market, assuming regulatory approval is obtained.
Financially, H.C. Wainwright noted that Invivyd is expected to enter 2026 with approximately $227 million in cash reserves, highlighting the company’s strong liquidity as a foundation for continued R&D and commercial efforts. VYD2311 was identified as the principal value driver as the company looks toward mid-2026 and beyond.
Recent financial results further support this outlook. Invivyd’s fourth-quarter 2025 revenue from PEMGARDA increased by 25% year-over-year to $17.2 million, reflecting a 31% sequential increase compared to the previous quarter. The company ended the year with $226.7 million in cash and equivalents, bolstered by over $200 million raised through financing activities in the second half of 2025.
Additionally, Invivyd announced plans to initiate a Phase 2 clinical trial by mid-2026 testing its monoclonal antibody candidate VYD2311 for patients suffering from Long COVID. This study will be conducted in partnership with the SPEAR Study Group, which includes researchers from Mount Sinai and the PolyBio Research Foundation.
Analyst coverage remains supportive, with BTIG affirming a Buy rating and a $10.00 target, citing the potential impact of Invivyd’s Long COVID therapy. Complementing these developments, Invivyd revealed a collaboration with Olympic gold medalist Lindsey Vonn, who will spearhead a national educational campaign on antibodies launching in early spring 2026, aimed at raising public awareness of antibody science.